When asked about the study, Novo Nordisk said it "remains confident in the benefit-risk profile of our GLP-1 medicines, when used consistent with their indications and product labeling." "Semaglutides efficacy and safety have been extensively demonstrated in people with obesity/overweight with robust evidence for improving health outcomes," the company noted in a statement to TODAY.com
Designed by experts and backed by science, Noom offers a personalized weight-loss experience that helps you build healthier habits, shift your mindset, and get lasting results
Maintaining open communication with your healthcare team ensures safe, effective treatment and allows for timely adjustments to your diabetes management plan
Never Mix SYMLIN And Insulin Inform patients that SYMLIN and insulin should always be administered as separate injections and never be mixed
Be on the lookout for rash, skin blisters or new swelling which could indicate an allergic reaction to the therapy